Related Experiment Videos
Pharmacogenetics of statins therapy.
Luca Puccetti1, Maurizio Acampa, Alberto Auteri
1Department of Clinical Medicine and Immunological Sciences, Section of Internal Medicine, University of Siena, Siena, Italy. puccetti@unisi.it
Recent Patents on Cardiovascular Drug Discovery
|January 29, 2008
Summary
Pharmacogenomics helps personalize statin therapy by examining genetic variations that influence drug response. Understanding these genetic factors can improve treatment effectiveness for cardiovascular disease patients.
Area of Science:
- Pharmacogenomics and Cardiovascular Therapeutics
Background:
- Cardiovascular disease is the leading global cause of death.
- Statins are primary treatments for coronary heart disease and atherosclerosis.
- Individual responses to statin therapy vary significantly.
Purpose of the Study:
- To explore the role of pharmacogenomics in understanding variable statin response.
- To identify genetic determinants of drug responsiveness.
- To review recent pharmacogenomic and pharmacogenetic patents related to statins.
Main Methods:
- Investigating genetic polymorphisms in three candidate gene groups: drug metabolism/transport, drug mechanism/pathways, and disease-related proteins.
- Analyzing genetic variations influencing lipid and lipoprotein metabolism.
- Summarizing recent pharmacogenomic and pharmacogenetic literature.
Main Results:
- Genetic variations significantly contribute to interindividual differences in statin efficacy.
- Candidate genes involved in pharmacokinetics, pharmacodynamics, and disease pathways are crucial.
- Pharmacogenomic insights can guide personalized statin treatment strategies.
Conclusions:
- Pharmacogenomics offers a powerful approach to optimize statin therapy.
- Identifying genetic markers can predict patient response to statins.
- Further research into genetic variations will enhance cardiovascular disease management.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...